Numbers

Figures converted from CNY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Numbers

Yatsen reports a 78% gross-margin business that has not yet earned an operating dollar in eight years and trades at 0.06x sales because the market has stopped believing the bridge from gross profit to net profit will ever be built. The whole investment case lives in two numbers — selling & marketing as a percent of revenue, and the cash buffer measured in years. Everything else is a derivative of those two. FY2025 was the first year both moved in the right direction at the same time, and the stock is priced as if that will not continue.

Quality Scorecard — Is This Business Built to Last?

External quality scores are unavailable for this ADR; the table below substitutes computed indicators from the eight-year filings. The verdict is unusual: the asset side of the balance sheet is healthier than almost any peer (zero financial debt, US$151M of cash and short-term investments, current ratio of 3.6x), but the income statement still has not converted that fortress into profits.

The scorecard sums to a fortress balance sheet wrapped around a leaky income statement. Predictability is the single weakest line — three platform-mix shocks in five years means historical earnings are a poor estimate of future earnings either way.

Revenue & Earnings Power — Eight Years In One Chart

Two things you cannot un-see: revenue collapsed 35% in a single year (FY2021 to FY2022) and has clawed back only halfway, and the FY2020 net loss of US$389M is roughly twice the entire current market cap measured in dollars. The FY2025 net loss of US$11M is the smallest since 2019 — within striking distance of the breakeven the company has not crossed since the IPO year.

Margin Architecture — The Mix Shift Showing Up In Real Time

Gross margin has expanded 1,560 basis points in seven years — entirely from mix shift toward premium skincare and discount discipline. Operating margin closed a 47-point gap with gross margin in the same window, the bottleneck being selling & marketing intensity (the gap between the green and amber lines). The thesis stands or falls on whether the amber line keeps converging on zero.

The Quarterly Trajectory — Recent Direction Matters Most

Q4 2025 (US$194M revenue, −0.9% operating margin) is the strongest single-quarter print since the platform-mix break. The slope of the right-hand chart matters more than any individual point: four straight quarters of compressing operating losses, while revenue re-accelerated to +18% YoY in Q4. This is the "is the corner real?" chart.

Cash Generation — Are The Earnings Real?

Operating cash flow has consistently been less negative than net income — D&A and stock-based compensation absorb a large chunk of the GAAP loss. FY2025 estimated operating cash burn of roughly US$14M against a US$11M net loss is a roughly 1.2x ratio — the first year cash burn approached the size of accounting loss in a healthy way. Capex is asset-light at US$6-9M annually (under 1.5% of revenue), so FCF and CFO march in lockstep. The honest framing: this is no longer a cash-incinerating business; it is a slow-bleed business.

Capital Allocation — Where The IPO Money Went

Yatsen has never paid a dividend and has no debt to service, so capital allocation is binary: cash either sits, gets returned via buybacks, or funds M&A. Of the US$1.02B raised at the 2020 IPO, roughly US$675M has been consumed by operating losses and acquisition writedowns (Galénic, DR.WU, Eve Lom), and another US$210M has gone out via buybacks and ADS programs. The March 2026 announcement of a US$120M convertible from Trustar Capital signals management wants firepower again — the question is whether the next dollar gets allocated more disciplined than the last one.

Balance Sheet Health — The Reason This Stock Can Survive Anything

Goodwill has been written down from US$137M (FY2021 peak) to US$22M — the worst of the M&A-spree damage is already behind in the P&L but still sits in the equity base via the US$1.16B accumulated deficit. With zero financial debt and US$151M of immediate liquidity against a roughly US$14M annual operating cash burn, the math says the company has 11 years before the buffer is exhausted at current run-rate. That number could easily double if FY2025's compressing-burn trajectory continues.

Valuation — At The Bottom Of Its Own Range

P/S has spent five quarters compressed in the 0.27–0.30x band — a multiple normally reserved for melting-ice-cube assets. But the financial profile underneath is improving during that compression, not deteriorating: gross margin expanded 200 bps, skincare share crossed half, and operating loss narrowed to under 5% of sales. Either the market is correct that this is a structurally low-quality asset and the multiple is permanent, or the multiple is a 60-70% discount to fair value of a sub-scale brand-house with a fortress balance sheet. EV/Revenue of 0.06x — net of cash, the operating business is being priced near zero — captures how much capitulation is in the quote.

Peer Comparison — Same Industry, Five Different Realities

YSG carries the highest gross margin in the room and the lowest valuation — by an order of magnitude on P/S. The closest economic comparable is COTY (also at trough P/S, also working through brand-portfolio drag), trading at 0.37x sales versus YSG's 0.06x. Pricing YSG at COTY's multiple alone would imply a 6x rerating; that does not happen because the market doubts the demand durability, not the asset quality.

Yatsen is the only dot below the x-axis. Crossing it — even into low single-digit positive operating margin — would relocate this name into the "small-cap c-beauty turnaround" cohort the market currently does not assign to the equity. The chart is the entire investment proposition in one image.

Fair Value & Scenarios

The book-value defense (US$430M equity, of which US$151M is cash) sets a hard floor: net cash alone is roughly US$148M against a US$182M market cap, leaving the operating brand portfolio priced at US$34M — for a business that did US$597M in revenue at 78% gross margin. From here, three reasonable scenarios on a 12-month horizon:

The fair-value range is exceptionally wide — that is what trough valuations look like in turnarounds. The asymmetry sits with the Bull case only if the next four prints continue the FY2025 margin trajectory. If they do not, the Bear case is not catastrophic (cash floor protects the equity) but the time-horizon for resolution lengthens past where most active funds will hold the position.

What The Numbers Say

The eight-year ledger confirms that Yatsen's gross margin is durable, rising, and now best-in-peer-group; that the balance sheet is fortress-grade with zero debt and 11+ years of runway; and that FY2025 is the first year all three of revenue growth, margin expansion and cash burn moved in the right direction simultaneously. They contradict the residual market narrative that this is a melting Perfect Diary stub — color cosmetics is now a managed-decline cash unit and the company is materially a skincare house. What to watch in the next four quarters: whether Q1 2026 prints inside the 15-30% revenue-growth guidance, whether selling & marketing as a percent of revenue stays below 60% outside Double-11 quarters, and what the US$120M Trustar convertible buys — accretive skincare brands or another Eve-Lom-style writedown waiting to happen. The numbers say this is a four-quarter binary; the price says it is already over.